Clinical Trials

Product/drug development
  1. A Phase 2, multi-center, randomized, open-label, dose escalation study to determine safety of single (QD) and multiple (3 QD) doses of KAE609, given to adults with uncomplicated Plasmodium falciparum malaria.
  2. prospective study to estimate the incidence of diseases specified as adverse events of special interest, of other adverse events leading to hospitalization or death, and of meningitis in infants and young children in Sub-Saharan Africa prior to implementation of the RTS,S/AS01E candidate vaccine.
Drug Discovery
  1. Erythrocyte invasion inhibitory antibody responses in malaria